West Pharmaceutical Services, Inc.

NYSE:WST Rapport sur les actions

Capitalisation boursière : US$22.3b

West Pharmaceutical Services Croissance future

Future contrôle des critères 1/6

West Pharmaceutical Services devrait augmenter ses bénéfices et son chiffre d'affaires de 12.7% et de 6.9% par an respectivement. Le BPA devrait croître de de 12% par an. Le rendement des capitaux propres devrait être 16.3% dans 3 ans.

Informations clés

12.7%

Taux de croissance des bénéfices

12.0%

Taux de croissance du BPA

Life Sciences croissance des bénéfices18.5%
Taux de croissance des recettes6.9%
Rendement futur des capitaux propres16.3%
Couverture par les analystes

Good

Dernière mise à jour29 Oct 2024

Mises à jour récentes de la croissance future

West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 27
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next

West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Jul 28
West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 27
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next

West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense

Oct 11

Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely

Sep 20
Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely

A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

Sep 02
A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Jul 28
West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)

Jul 25

Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?

Jul 15
Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?

We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt

Jun 27
We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt

Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

May 21
Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry

May 11

West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price

Mar 30
West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price

Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?

Mar 12
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?

Why West Pharma Is Far From Done

Feb 28

West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price

Feb 20
West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price

West Pharmaceutical Services: Still Too Expensive After The Recent Drop

Feb 20

What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?

Jan 10
What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?

West Pharmaceutical: Great Business, Not So Great Valuation

Jan 08

What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You

Dec 18
What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You

West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet

Nov 27
West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet

West Pharmaceutical Services: The Run Might Be Over

Oct 18

Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?

Sep 24
Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?

Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?

Aug 22
Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?

West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics

Aug 08

What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?

Jun 26
What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?

West Pharmaceutical: Hard To Justify The Price

May 26

Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?

May 16
Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?

At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?

Mar 20
At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?

West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture

Feb 28
West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture

West Pharmaceutical Q4 2022 Earnings Preview

Feb 15

West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet

Jan 31
West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet

West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive

Dec 19

West Pharmaceutical declares $0.19 dividend

Dec 13

Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching

Nov 29
Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching

Prévisions de croissance des bénéfices et des revenus

NYSE:WST - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20263,3396565538608
12/31/20253,06655645174310
12/31/20242,88347924463410
9/30/20242,876500322702N/A
6/30/20242,877525357752N/A
3/31/20242,929569386757N/A
12/31/20232,950593415777N/A
9/30/20232,927559420768N/A
6/30/20232,866519397707N/A
3/31/20232,884552410711N/A
12/31/20222,887586439724N/A
9/30/20222,909631388654N/A
6/30/20222,929686402675N/A
3/31/20222,881684382647N/A
12/31/20212,832662331584N/A
9/30/20212,681613341572N/A
6/30/20212,523519287500N/A
3/31/20212,326423307504N/A
12/31/20202,147346298473N/A
9/30/20202,037312272430N/A
6/30/20201,945286277420N/A
3/31/20201,888261247377N/A
12/31/20191,840242241367N/A
9/30/20191,792230215334N/A
6/30/20191,767229201314N/A
3/31/20191,745219186291N/A
12/31/20181,717207184289N/A
9/30/20181,711155193297N/A
6/30/20181,677151N/A284N/A
3/31/20181,627133N/A288N/A
12/31/20171,599151N/A263N/A
9/30/20171,566190N/A254N/A
6/30/20171,544176N/A246N/A
3/31/20171,535182N/A237N/A
12/31/20161,509144N/A219N/A
9/30/20161,487138N/A216N/A
6/30/20161,454102N/A216N/A
3/31/20161,42685N/A217N/A
12/31/20151,40096N/A212N/A
9/30/20151,39094N/A190N/A
6/30/20151,401123N/A186N/A
3/31/20151,411133N/A172N/A
12/31/20141,421127N/A183N/A
9/30/20141,414119N/A206N/A
6/30/20141,400115N/A195N/A
3/31/20141,376108N/A210N/A
12/31/20131,368112N/A221N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de WST ( 12.7% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de WST ( 12.7% par an) devraient croître plus lentement que le marché US ( 15.4% par an).

Croissance élevée des bénéfices: Les bénéfices de WST devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de WST ( 6.9% par an) devrait croître plus lentement que le marché de US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de WST ( 6.9% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de WST devrait être faible dans 3 ans ( 16.3 %).


Découvrir les entreprises en croissance